- Home
- CHYM vs RPRX Comparison
CHYM vs RPRX Comparison
Compare CHYM & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHYM
- RPRX
- Stock Information
- Founded
- CHYM 2012
- RPRX 1996
- Country
- CHYM United States
- RPRX United States
- Employees
- CHYM N/A
- RPRX N/A
- Industry
- CHYM Finance: Consumer Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CHYM Finance
- RPRX Health Care
- Exchange
- CHYM Nasdaq
- RPRX Nasdaq
- Market Cap
- CHYM 13.5B
- RPRX 13.9B
- IPO Year
- CHYM 2025
- RPRX 2020
- Fundamental
- Price
- CHYM $29.91
- RPRX $34.48
- Analyst Decision
- CHYM
- RPRX Strong Buy
- Analyst Count
- CHYM 0
- RPRX 3
- Target Price
- CHYM N/A
- RPRX $47.33
- AVG Volume (30 Days)
- CHYM 12.3M
- RPRX 4.9M
- Earning Date
- CHYM 01-01-0001
- RPRX 08-07-2025
- Dividend Yield
- CHYM N/A
- RPRX 2.52%
- EPS Growth
- CHYM N/A
- RPRX 37.60
- EPS
- CHYM N/A
- RPRX 2.45
- Revenue
- CHYM $1,800,041,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- CHYM N/A
- RPRX $29.35
- Revenue Next Year
- CHYM N/A
- RPRX $7.58
- P/E Ratio
- CHYM N/A
- RPRX $14.24
- Revenue Growth
- CHYM 30.88
- RPRX 1.13
- 52 Week Low
- CHYM $31.21
- RPRX $24.05
- 52 Week High
- CHYM $44.94
- RPRX $35.38
- Technical
- Relative Strength Index (RSI)
- CHYM N/A
- RPRX 57.70
- Support Level
- CHYM N/A
- RPRX $34.42
- Resistance Level
- CHYM N/A
- RPRX $35.38
- Average True Range (ATR)
- CHYM 0.00
- RPRX 0.60
- MACD
- CHYM 0.00
- RPRX 0.09
- Stochastic Oscillator
- CHYM 0.00
- RPRX 68.13
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.